- Home
- FTFT vs SNGX Comparison
FTFT vs SNGX Comparison
Compare FTFT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- SNGX
- Stock Information
- Founded
- FTFT N/A
- SNGX 1987
- Country
- FTFT United States
- SNGX United States
- Employees
- FTFT N/A
- SNGX N/A
- Industry
- FTFT Business Services
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- SNGX Health Care
- Exchange
- FTFT Nasdaq
- SNGX Nasdaq
- Market Cap
- FTFT 5.9M
- SNGX 6.5M
- IPO Year
- FTFT N/A
- SNGX 1987
- Fundamental
- Price
- FTFT $1.15
- SNGX $1.37
- Analyst Decision
- FTFT
- SNGX
- Analyst Count
- FTFT 0
- SNGX 0
- Target Price
- FTFT N/A
- SNGX N/A
- AVG Volume (30 Days)
- FTFT 48.8K
- SNGX 147.3K
- Earning Date
- FTFT 08-18-2025
- SNGX 08-08-2025
- Dividend Yield
- FTFT N/A
- SNGX N/A
- EPS Growth
- FTFT N/A
- SNGX N/A
- EPS
- FTFT N/A
- SNGX N/A
- Revenue
- FTFT $2,031,913.00
- SNGX $2,342.00
- Revenue This Year
- FTFT N/A
- SNGX N/A
- Revenue Next Year
- FTFT N/A
- SNGX N/A
- P/E Ratio
- FTFT N/A
- SNGX N/A
- Revenue Growth
- FTFT N/A
- SNGX N/A
- 52 Week Low
- FTFT $1.01
- SNGX $1.31
- 52 Week High
- FTFT $5.70
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- FTFT 39.32
- SNGX 23.71
- Support Level
- FTFT $1.01
- SNGX $1.31
- Resistance Level
- FTFT $1.16
- SNGX $1.95
- Average True Range (ATR)
- FTFT 0.09
- SNGX 0.07
- MACD
- FTFT 0.01
- SNGX -0.05
- Stochastic Oscillator
- FTFT 25.00
- SNGX 9.56
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).